On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, AbbVie presented new results from its post-hoc analysis of the Phase III TEMPO-1 (NCT04201093) and TEMPO-2 (NCT04223193) clinical trials, which sought to evaluate the safety and efficacy of tavapadon—an oral once-daily D1/D5 partial agonist—as a monotherapy in early Parkinson’s disease (PD).
TEMPO-1 used fixed dosing (5mg and 15mg) and TEMPO-2 used flexible dosing (5mg–15mg) across a 27-week, placebo-controlled design. Both trials had previously demonstrated statistically significant improvement in motor function versus placebo on the MDS-UPDRS severity index, as presented in Q4 2024. This post-hoc analysis extended those findings by evaluating tavapadon’s effect specifically on tremor, one of the most bothersome symptoms reported by patients in early PD.
Go deeper with GlobalData
The post-hoc analysis results were consistent with the previously reported results. Seven of 11 tremor-related MDS-UPDRS items showed statistically significant improvement with tavapadon versus placebo across both trials, demonstrating a breadth of effect across postural, kinetic, and rest tremor subtypes. Additionally, tavapadon’s effect in treating tremors was found to be statistically significant compared with placebo. The most striking signal was in rest tremor consistency (MDS-UPDRS item 3.18): in TEMPO-1, tavapadon 5mg and 15mg achieved improvements of 41% and 50%, respectively, compared to just 6% for placebo. In TEMPO-2, 57% of tavapadon-treated participants experienced improvement in rest tremor consistency versus 40% on placebo. Patient-reported experience of tremor (MDS-UPDRS Part II, item 2.10) improved by 33% with tavapadon in TEMPO-1 and by 32% vs. 6% for placebo in TEMPO-2, with a greater proportion of tavapadon-treated participants also achieving complete symptom resolution across most tremor items compared with placebo.
The positive sentiment of this drug is shared by key opinions leaders (KOLs) previously interviewed by GlobalData, frequently citing its promising efficacy data and its selective D1/D5 mechanism as a meaningful clinical differentiator, noting that D2/D3 overactivation is the primary driver of the side effects that force de-escalation or discontinuation of existing dopamine agonists in real-world practice. KOLs also cited tavapadon’s once-daily oral dosing as commercially important in a class where compliance and tolerability drive long-term treatment decisions as much as efficacy. Furthermore, they have also highlighted tavapadon’s potential use in addressing dyskinesia, as well as its ability to work both as monotherapy in early PD and as adjunctive therapy in advanced PD, a dual positioning that broadens its addressable patient population considerably. The newly presented tremor data is likely to further reinforce tavapadon’s clinical positioning in the monotherapy space. Tavapadon will enter a competitive but commercially attractive market. According to GlobalData’s Drug Database, there are currently six dopamine agonists marketed across the seven major pharmaceutical markets (7MM: the US, France, Germany,Italy, Spain, the UK, and Japan), including generic ropinirole and the rotigotine patch—both well-established and inexpensive. In terms of pipeline products, IRLAB Therapeutic’s mesdopetam is another dopamine agonist currently undergoing Phase III clinical study. However, unlike tavapadon, mesdopetam is positioned as a treatment for levodopa-induced dyskinesia (LID), while tavapadon is positioned to treat the broad motor symptoms in treatment-naïve PD patients.
The tremor post-hoc data is strategically important ahead of a likely regulatory submission, as efficacy reported across multiple tremor subtypes strengthens the product label claims for a symptom that is consistently cited as a high unmet need and treatment priority by KOLs. While the previously reported primary endpoint results and the tolerability profile already provide a solid foundation for tavapadon, the open-label extension data will be critical in determining whether motor benefits—including tremor suppression—are durable enough to justify long-term use over cheaper generic alternatives in a cost-sensitive market.
